Summary

KEY FINDINGS
The global 3D bioprinting market is predicted to record a CAGR of 16.69% during the forecast period, 2023-2032. The market growth is attributed to the high prevalence of chronic disease, the growing focus on regenerative medicine, R&D investments and technological advancements, and the increasing elderly population.
MARKET INSIGHTS
3D bioprinting is an additive manufacturing process that uses biomaterials and cells like nutrients and living cells instead of traditional plastics and metals to create artificial structures that mimic natural human tissues.
The growing elderly population is a key growth driver of the global 3D bioprinting market growth. The aging population is increasingly vulnerable to bone injuries, obesity, and osteoporosis, which further contributes to the failure of orthopedic implants. In this regard, 3D bioprinted bone can be personalized to patient-specific needs.
As per the Oncology Nursing Society, around 60% of all cancers in the US occur in the older population. Such aspects raise the need for a better understanding of the drugs required for the treatment. In addition, researchers can get a better idea about how tumors react to certain drugs through 3D bioprinting tumors. Accordingly, 3D bioprinted tumors can be used to experiment with new drugs and treatments. As a result, such factors are expected to propel growth opportunities for 3D bioprinting. However, the global 3D bioprinting market growth is restrained by a lack of skilled professionals and high costs.
REGIONAL INSIGHTS
The global 3D bioprinting market growth assessment includes the geographical evaluation of North America, Europe, Asia-Pacific, and Rest of World. North America is the largest revenue-generating region in the global market, accredited to the huge geriatric population and high prevalence of cardiovascular diseases.
COMPETITIVE INSIGHTS
Prominent market leaders are investing in merger & acquisition activities and product innovations to maintain a competitive edge in the market. Some of the leading companies in the market are Advanced Solutions Life Sciences, Cyfuse Biomedical KK, GeSiM GmbH, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON 3D BIOPRINTING MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. EMERGENCE OF 4D BIOPRINTING AS A SUBSTITUTE FOR 3D BIOPRINTING
2.5.2. PERSONALIZED MEDICINE LIKELY TO BOOST 3D BIOPRINTING
2.5.3. RISING INTEREST IN THE APPLICATION OF BIOPRINTING AGAINST THE SARS-COV-2 VIRUS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SURGING GERIATRIC POPULATION
3.1.2. TECHNOLOGICAL ADVANCEMENTS AND R&D INVESTMENTS
3.1.3. RISING FOCUS ON REGENERATIVE MEDICINE
3.1.4. HIGH PREVALENCE OF CHRONIC CONDITIONS
3.2. KEY RESTRAINTS
3.2.1. OPERATIONAL CHALLENGES DURING MANUFACTURING
3.2.2. EXORBITANT COSTS OF 3D BIOPRINTERS
3.2.3. LACK OF TRAINED PROFESSIONALS
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.4.1. GROWTH PROSPECT MAPPING IN UNITED STATES
4.4.2. GROWTH PROSPECT MAPPING IN GERMANY
4.4.3. GROWTH PROSPECT MAPPING IN CHINA
4.4.4. GROWTH PROSPECT MAPPING FOR BRAZIL
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. DESIGN & SOFTWARE PROVIDERS
4.7.2. PROTOTYPE PRODUCTION
4.7.3. DISTRIBUTION
4.7.4. END-USERS
5. MARKET BY COMPONENT
5.1. 3D BIOPRINTER
5.2. BIOINK
6. MARKET BY BIOMATERIAL
6.1. HYDROGEL
6.2. LIVING CELLS
6.3. EXTRACELLULAR MATRICES
6.4. OTHER BIOMATERIALS
7. MARKET BY TECHNOLOGY
7.1. MAGNETIC LEVITATION BIOPRINTING
7.2. INKJET-BASED BIOPRINTING
7.3. SYRINGE/EXTRUSION-BASED BIOPRINTING
7.4. LASER-ASSISTED BIOPRINTING
7.5. OTHER TECHNOLOGIES
8. MARKET BY APPLICATION
8.1. DRUG TESTING & DEVELOPMENT
8.2. TISSUE ENGINEERING & REGENERATIVE MEDICINE
8.3. FOOD TESTING
8.4. RESEARCH
8.5. OTHER APPLICATIONS
9. MARKET BY END-USER
9.1. HOSPITALS
9.2. BIOPHARMACEUTICALS COMPANIES
9.3. RESEARCH ORGANIZATIONS AND ACADEMIC INSTITUTES
9.4. OTHER END-USERS
10. GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1. MARKET SIZE & ESTIMATES
10.1.2. NORTH AMERICA 3D BIOPRINTING MARKET DRIVERS
10.1.3. NORTH AMERICA 3D BIOPRINTING MARKET CHALLENGES
10.1.4. NORTH AMERICA 3D BIOPRINTING MARKET REGULATORY FRAMEWORK
10.1.5. KEY PLAYERS IN NORTH AMERICA 3D BIOPRINTING MARKET
10.1.6. COUNTRY ANALYSIS
10.1.6.1. UNITED STATES
10.1.6.1.1. UNITED STATES 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.1.6.2. CANADA
10.1.6.2.1. CANADA 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.2. EUROPE
10.2.1. MARKET SIZE & ESTIMATES
10.2.2. EUROPE 3D BIOPRINTING MARKET DRIVERS
10.2.3. EUROPE 3D BIOPRINTING MARKET CHALLENGES
10.2.4. EUROPE 3D BIOPRINTING MARKET REGULATORY FRAMEWORK
10.2.5. KEY PLAYERS IN EUROPE 3D BIOPRINTING MARKET
10.2.6. COUNTRY ANALYSIS
10.2.6.1. UNITED KINGDOM
10.2.6.1.1. UNITED KINGDOM 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.2.6.2. GERMANY
10.2.6.2.1. GERMANY 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.2.6.3. FRANCE
10.2.6.3.1. FRANCE 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.2.6.4. ITALY
10.2.6.4.1. ITALY 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.2.6.5. SPAIN
10.2.6.5.1. SPAIN 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.2.6.6. NORDIC COUNTRIES
10.2.6.6.1. NORDIC COUNTRIES 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.2.6.7. REST OF EUROPE
10.2.6.7.1. REST OF EUROPE 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.3. ASIA-PACIFIC
10.3.1. MARKET SIZE & ESTIMATES
10.3.2. ASIA-PACIFIC 3D BIOPRINTING MARKET DRIVERS
10.3.3. ASIA-PACIFIC 3D BIOPRINTING MARKET CHALLENGES
10.3.4. ASIA-PACIFIC 3D BIOPRINTING MARKET REGULATORY FRAMEWORK
10.3.5. KEY PLAYERS IN ASIA-PACIFIC 3D BIOPRINTING MARKET
10.3.6. COUNTRY ANALYSIS
10.3.6.1. CHINA
10.3.6.1.1. CHINA 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.3.6.2. JAPAN
10.3.6.2.1. JAPAN 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.3.6.3. INDIA
10.3.6.3.1. INDIA 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.3.6.4. SOUTH KOREA
10.3.6.4.1. SOUTH KOREA 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.3.6.5. SINGAPORE
10.3.6.5.1. SINGAPORE 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.3.6.6. THAILAND
10.3.6.6.1. THAILAND 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.3.6.7. AUSTRALIA & NEW ZEALAND
10.3.6.7.1. AUSTRALIA & NEW ZEALAND 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.3.6.8. REST OF ASIA-PACIFIC
10.3.6.8.1. REST OF ASIA-PACIFIC 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.4. REST OF WORLD
10.4.1. MARKET SIZE & ESTIMATES
10.4.2. REST OF WORLD 3D BIOPRINTING MARKET DRIVERS
10.4.3. REST OF WORLD 3D BIOPRINTING MARKET CHALLENGES
10.4.4. KEY PLAYERS IN REST OF WORLD 3D BIOPRINTING MARKET
10.4.5. REGIONAL ANALYSIS
10.4.5.1. LATIN AMERICA
10.4.5.1.1. LATIN AMERICA 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.4.5.2. MIDDLE EAST & AFRICA
10.4.5.2.1. MIDDLE EAST & AFRICA 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
11. COMPETITIVE LANDSCAPE
11.1. KEY STRATEGIC DEVELOPMENTS
11.1.1. MERGERS & ACQUISITIONS
11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
11.1.3. PARTNERSHIPS & AGREEMENTS
11.2. COMPANY PROFILES
11.2.1. 3D BIOPRINTING SOLUTIONS
11.2.1.1. COMPANY OVERVIEW
11.2.1.2. PRODUCTS LIST
11.2.2. ADVANCED SOLUTIONS LIFE SCIENCES
11.2.2.1. COMPANY OVERVIEW
11.2.2.2. PRODUCTS LIST
11.2.3. ALLEVI
11.2.3.1. COMPANY OVERVIEW
11.2.3.2. PRODUCTS LIST
11.2.4. CELLINK
11.2.4.1. COMPANY OVERVIEW
11.2.4.2. PRODUCTS LIST
11.2.4.3. STRENGTHS & CHALLENGES
11.2.5. COLLPLANT BIOTECHNOLOGIES LTD
11.2.5.1. COMPANY OVERVIEW
11.2.5.2. PRODUCTS LIST
11.2.6. CYFUSE BIOMEDICAL KK
11.2.6.1. COMPANY OVERVIEW
11.2.6.2. PRODUCTS LIST
11.2.6.3. STRENGTHS & CHALLENGES
11.2.7. ENVISIONTEC ṁ INC
11.2.7.1. COMPANY OVERVIEW
11.2.7.2. PRODUCTS LIST
11.2.7.3. STRENGTHS & CHALLENGES
11.2.8. GESIM GMBH
11.2.8.1. COMPANY OVERVIEW
11.2.8.2. PRODUCTS LIST
11.2.8.3. STRENGTHS & CHALLENGES
11.2.9. INVENTIA LIFE SCIENCE PTY LTD
11.2.9.1. COMPANY OVERVIEW
11.2.9.2. PRODUCTS LIST
11.2.10. ORGANOVO HOLDINGS INC
11.2.10.1. COMPANY OVERVIEW
11.2.10.2. PRODUCTS LIST
11.2.10.3. STRENGTHS & CHALLENGES
11.2.11. REGEMAT 3D
11.2.11.1. COMPANY OVERVIEW
11.2.11.2. PRODUCTS LIST
11.2.11.3. STRENGTHS & CHALLENGES
11.2.12. REGENHU
11.2.12.1. COMPANY OVERVIEW
11.2.12.2. PRODUCTS LIST
11.2.12.3. STRENGTHS & CHALLENGES
11.2.13. REVOTEK CO LTD
11.2.13.1. COMPANY OVERVIEW
11.2.13.2. PRODUCTS LIST
11.2.14. ROKIT HEALTHCARE INC
11.2.14.1. COMPANY OVERVIEW
11.2.14.2. PRODUCTS LIST
11.2.15. STRATASYS LTD
11.2.15.1. COMPANY OVERVIEW
11.2.15.2. PRODUCTS LIST